Pharmacokinetics of midazolam tablet in different Chinese ethnic groups

Journal of Clinical Pharmacy and Therapeutics

Volumn 36, Issue 3, 2011, Pages 406-411

  Guo, T ^a   Mao, G F ^a   Xia, D Y ^a   Su, X Y ^a   Zhao, L S ^a  

^a Shenyang Northern Hospital   (China)

Author keywords

Han; HPLC; Hui; Korean; midazolam; Mongolian; pharmacokinetics; Uygur

Indexed keywords

MIDAZOLAM;

ADULT; AREA UNDER THE CURVE; ARTICLE; CHINA; CLINICAL TRIAL; COMPARATIVE STUDY; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG HALF LIFE; ETHNICITY; FEMALE; HALF LIFE TIME; HUMAN; HUMAN EXPERIMENT; MALE; MAXIMUM PLASMA CONCENTRATION; NAUSEA; NORMAL HUMAN; SEX DIFFERENCE; SINGLE DRUG DOSE; TABLET FORMULATION;

ADULT; ANTI-ANXIETY AGENTS; ASIAN CONTINENTAL ANCESTRY GROUP; BIOTRANSFORMATION; CHINA; ETHNIC GROUPS; FEMALE; HALF-LIFE; HUMANS; MALE; METABOLIC CLEARANCE RATE; MIDAZOLAM; TABLETS; YOUNG ADULT;

EID: 79955749309     PISSN: 02694727     EISSN: 13652710     Source Type: Journal    
DOI: 10.1111/j.1365-2710.2010.01178.x     Document Type: Article

References (17)

1. Heizmann P, Eckert M, Ziegler WH, (1983) Pharmacokinetics and bioavailability of midazolam in man. British journal of Clinical Pharmacology, 16, 43S-49S. (Pubitemid 13006585)
2. 14C-midazolam in humans following oral dosing. Arzneimittelforchung/ Drug Research, 31, 2220-2223. (Pubitemid 12222301)
3. Thummel K, O'shea D, Paine M, Shen D, Kunze K, Perkins J, Wilkinson G, (1996) Oral first-pass elimination of midazolam involves both gastrointestinal and hepatic CYP3A-mediated metabolism. Clinical Pharmacology Therapeutics, 59, 491-502. (Pubitemid 26193889)
4. Kronbach T, Mathys D, Umeno M, Gonzalez FJ, Meyer UA, (1989) Oxidation of midazolam and triazolam by human liver cytochrome P450IIIA4. Molecular Pharmacology, 36, 89-96. (Pubitemid 19191264)
5. Wandel C, Booker R, Bohrer H, Browne A, Riigheimer E, Martin E, (1999) Midazolam is metabolized by at least three different cytochrome P450 enzymes. British Journal of Anaesthetics, 73, 658-661. (Pubitemid 24323498)
6. Johnson JA, (2000) Predictability of the effects of race or ethnicity on pharmacokinetics of drugs. International Journal of Clinical Pharmacology and Therapeutics, 38, 53-60. (Pubitemid 30077979)
7. Kinirons MT, Lang CC, He HB, Ghebreselasie K, Shay S, Robin DW, Wood AJJ, (1996) Triazolam pharmacokinetics and pharmacodynamics in Caucasians and Southern Asians: ethnicity and CYP3A activity. British Journal of Clinical Pharmacology, 41, 69-72. (Pubitemid 26009912)
8. Mancinelli LM, Frassetto L, Floren LC, et al. (2001) The pharmacokinetics and metabolic disposition of tacrolimus: a comparison across ethnic groups. Clinical Pharmacology Therapeutics, 69, 24-31. (Pubitemid 32108668)
9. Lilia CT, Gilberto CH, Francisco JFM, (1999) Pharmacokinetics of midazolam in Mexicans. Evidence for interethnic variability[J]. Clinical Drug Investigation, 17, 233-239.
10. Guo H, Yan JW, Jiao ZP, et al. (2008) Genetic polymorphisms for 17 Y-chromosomal STRs haplotypes in Chinese Hui population. Legal Medicine, 10, 163-169.
11. Zhu BF, Shen CM, Yang TH, et al. (2008) Genetic analysis of 17 Y-chromosomal STRs haplotypes of Chinese Tibetan ethnic group residing in Qinghai province of China. Forensic Science International, 175, 238-243.
12. Zhang YJ, Zhang HJ, Cui Y, et al. (2007) Population genetics for Y-chromosomal STRs haplotypes of Chinese Korean ethnic group in northeastern China. Forensic Science International, 173, 197-203. (Pubitemid 47588729)
13. Zhu BF, Wang ZY, Yang CH, et al. (2005) Y-chromosomal STR haplotypes in Chinse Uigur ethnic group. International Journal of Legal Medicine, 119, 306-309. (Pubitemid 41253155)
14. n repeat polymorphism in six Chinese ethnic groups. Legal Medicine, 9, 330-331. (Pubitemid 47371104)
15. Li GC, Chen CY, Wang YH, (1997) comparative pharmacokinetic study on ciprofloxacin in healthy volunteers of the Han, Uygur and Kazak nationalities. Chinese Journal of Clinical Pharmacology, 13, 145-148.
16. Mao GF, Guo T, Xia DY, (2008) Determination of content of midazolam in human plasma by RP-HPLC method. Pharmaceutical Care and Research, 8, 297-299.
17. Belle DJ, Callaghan JT, Gorski JC, Maya JF, Mousa O, Wrighton SA, Hall SD, (2002) The effects of an oral contraceptive containing ethinyloestradiol and norgestrel on CYP3A activity. Journal of Clinical Pharmacology, 53, 67-74. (Pubitemid 34117741)